Patrick Schöffski, MD, on Eribulin for Soft-Tissue Sarcomas

2015 ASCO Annual Meeting
Tweet this page

Patrick Schöffski, MD, of the University Hospital Leuven, discusses a phase III study in which he and his colleagues found, for the first time in soft-tissue sarcomas, a significant overall survival benefit of a single agent compared to a standard treatment (Abstract LBA10502).

Advertisement

Advertisement



Advertisement